Disorders of neurotransmitter methabolism in children with autism spectrum disorders (review of literature and own data)

L.G. Kirillova, L.I. Tkachuk, A.A. Miroshnikov, A.A. Yuzva, O.I. Tsubko

Abstract


At the time when the number of children with autism spectrum disorders (ASD) is increasing, the number of studies that investigate the clinical features of the disease, pathogenesis, etiological factors and methods of treatment is increasing too. There is no single answer to the questions of etiology and pathogenesis of this disorder for today. In this article, we present modern literature data regarding the problem of neurotransmitter metabolism in children with ASD. Also, the data obtained during the determination of gamma-aminobutyric acid (GABA) concentration in the blood plasma of children with cognitive epileptiform disintegration (n = 45) and children with ASD without epileptic seizures (n = 15) are given. According to the results of the study, there was a decrease in the average concentration of GABA in children with cognitive epileptiform disintegration as compared to the control group (n = 12). There were no significant differences in the mean concentration of GABA between the group of children with ASD without epileptic seizures and the control group (p < 0.001). Our results and a review of literature data allow us to state the necessity of using drugs that regulate the metabolism of neurotransmitters, especially GABA, in the treatment of children with ASD.

Keywords


autism spectrum disorders; cognitive epileptiform disintegration; epilepsy; neurotransmitters; gamma-aminobutyric acid

References


Elsabbagh M., Divan G., Yun-Joo Koh Y.J. et al. Global prevalence of autism and other pervasive developmental disorders // Autism Res. — 2012. — 5(3). — Р. 160-79.

Розлади аутистичного спектра (розлади загального розвитку). Уніфікований клінічний протокол первинної, вторинної (спеціалізованої), третинної (високоспеціалізованої) медичної допомоги та медичної реабілітації: Наказ Міністерства охорони здоров’я України від 15 червня 2015 р. № 341.

Manzi B. Autism and metabolic diseases // J. Child Neurol. — 2008 Mar. — 23(3). — Р. 307-14. — Epub 2007, Dec 13.

Frye R.E. Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder // Epilepsy Behav. — 2015 Jun. — 47. — Р. 147-57. — doi: 10.1016/j.yebeh.2014.08.134. — Epub 2014, Nov 4.

Голимбет В.Е., Корень Е.В. Вариации числа копий в геноме — новая страница в генетических исследованиях в области психиатрии: международный проект PsychCNVs // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2010. — № 1. — С. 107-109.

Brooks-Kayal A. Molecular mechanisms of cognitive and behavioral comorbidities of epilepsy in children // Epilepsia. — 2011. — 52 (Suppl. 1). — Р. 13-20.

Гречанина Е.Я. Аутизм. Генетические и эпигенетические проблемы / Е.Я. Гречанина // Науковий журнал МОЗ України. — 2013. — № 2. — С. 29-48. — Режим доступу: http://nbuv.gov.ua/UJRN/njmoz_2013_2_5.

King B.H. Promising forecast for autism spectrum disorders // Journal of the American Medical Association. — 2015. — 313(15). — 1518-1519. — doi:10.1001/jama.2015.2628.

Frye R.E., Rossignol D.A. Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes // Clin. Med. Insights Pediatr. — 2016, Jun 15. — 10. — 43-56. — doi: 10.4137/CMPed.S38337. — Collection 2016.

Bowery N.G. Pharmacology of GABAB receptors // Glutamate and GABA Receptors and transporters: Structure, Function and Pharmacology / Egebjerg J., Schousboe A., Krogsgaard Larsen P., eds. — London: Taylor and Francis, 2002. — P. 287-304.

Brooks-Kayal A. Epilepsy and autism spectrum disorders: are there common developmental mechanisms? // Brain & Development. — 2010. — V. 32. — P. 731-738.

Блинов Д.В. Общность ряда нейробиологических процессов при расстройствах деятельности ЦНС // Эпилепсия и пароксизмальные состояния. — 2011. — № 3(2). — С. 28-33.

Веселовский Н.С., Федулова С.А., Костюк П.Г. Биофизика одиночного синапса. — Киев: Наукова думка, 2004. — 117 с.

Зенков Л.Р. Клиническая электроэнцефалография с элементами эпилептологии. — М.: МЕДпресс-информ, 2002. — С. 78; 85; 109-173; 203-223.

Menkes J.H., Sarnat H.B., Maria B.L. Child Neurology. —

th ed. — Lippincott Williams & Wilkins, 2006. — 1156 p.

David R.B., Bodeinsteiner J.B., Mandelbaum D.E. Clinical pediatric neurology. — New York: Demos Medical Publishing, 2009. — 622 p.

Абрамец И.И., Комиссаров И.В. Глутаматергические механизмы ишемических повреждений мозга (обзор литературы и собственных исследований) // Журнал АМН України. — 2001. — № 7(4). — С. 613-633.

Olsen R.W., Macdonald R.L. GABA A receptor complex structure and function // Glutamate and GABA Receptors and Transporters: Structure, Function and Pharmacology / Egebjerg J., Schousboe A., Krogsgaard Larsen P., eds. — London: Taylor and Francis, 2002. — Р. 202-235.

Schousboe A., Kanner B. GABA transporters: Functional and pharmacological properties // Glutamate and GABA Receptors and Transporters: Structure, Function and Pharmacology / Egebjerg J., Schousboe A., Krogsgaard Larsen P., eds. — London: Taylor and Francis, 2002. — Р. 337-349.

Watanabe M., Maemura K., Kanbara K., Tamayama T., Hayasaki H. GABA and GABA receptors in the central nervous system and other organs // Int. Rev. Cytol. — 2002. — Vol. 213. — P. 1-47.

Li K., Xu E. The role and the mechanism of gamma-aminobutyric acid during central nervous system development // Neurosci. Bull. — 2008. — Vol. 24(3). — P. 195-200.

Foster A.C., Kemp J.A. Glutamate- and GABA-based CNS therapeutics // Curr. Opin. Pharmacol. — 2006. — Vol. 6(1). —

P. 7-17.

Bormann J. The ‘ABC’ of GABA receptors // Trends Pharmacol. Sci. — 2000. — Vol. 21(1). — P. 16-19.

Johnston G.A.R. Molecular biology, pharmacology and physiology of GABAC receptors // The GABA Receptors / Enna S.J., Bowery N.G., eds. — New Jersey: Humana Press Inc., 1997. —

P. 297-323.

Rolf L., Haarmann F., Grotemeyer K.-N., Kehrer H. Serotonin and amino acid contents in platelets of autistic children // Acta Psychiatr. Scand. — 1993. — 87. — Р. 312-6.

Cohen B. Elevated levels of plasma and urine gamma-aminobutyric acid: a case study of an autistic child (letter) // Autism. — 1999. — 3. — Р. 437-40.

Hussman J. Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism (letter) // J. Autism Dev. Disord. — 2001. — 31. — Р. 247-8.

Rossignol D.A., Frye R.E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis // Mol. Psychiatry. — 2012. — 17(3). — Р. 290-314.

Jakobs C. et al. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error ofmetabolism // Clin. Chim. Acta. — 1981. — 111. — Р. 169-78.

Pearl P.L. et al. Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency // Neurology. — 2009. — 73. — Р. 423-9.

Knerr I. et al. Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients // CNS Spectr. — 2008. — 13. — Р. 598-605.

Pearl P.L., Gibson K.M. Clinical aspects of the disorders of GABA metabolism in children // Curr. Opin. Neurol. — 2004. — 17. — Р. 107-13.

Pearl P.L. et al. Succinic semialdehyde dehydrogenase deficiency in children and adults // Ann. Neurol. — 2003. — 54(Suppl. 6). — Р. 73-80.

Basura G.J. et al. Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry // Eur. J. Pediatr. — 2009. — 168. — Р. 697-704.

Gupta V.K. et al. Pyridoxine-dependent seizures: a casereport and a critical review of the literature // J. Paediatr. Child Health. — 2001. — 37. — Р. 592-6.

Mills P.B. et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures // Nat. Med. — 2006. — 12. — Р. 307-9.

Plecko B. et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epi-lepsy and mutations of the antiquitin (ALDH7A1) gene // Hum. Mutat. — 2007. — 28. — Р. 19-26.

Gospe S.M. Pyridoxine-dependent seizures: findings from recent studies pose new questions // Pediatr. Neurol. — 2002. — 26. — Р. 181-5.

Mahajan R., Bernal M.P., Panzer R. et al. Autism Speaks Autism Treatment Network Psychopharmacology C. Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders // Pediatrics. — 2012. — 130(Suppl. 2). — Р. 125-38.

Arnold L.E., Aman M.G., Cook A.M. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial // J. Am. Acad. Child Adolesc. Psychiatry. — 2006. — 45(10). — Р. 1196-205.

Ji N., Findling R.L. An update on pharmacotherapy for autism spectrum disorder in children and adolescents // Curr. Opin. Psychiatry. — 2015. — 28(2). — Р. 91-101.

Gordon I. et al. Oxytocin enhances brain function in children with autism // Proc. Natl Acad. Sci USA. — 2013, Dec 24. — 110(52).




DOI: https://doi.org/10.22141/2224-0713.4.90.2017.107256

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru